OverviewChartProfileKey statisticsFinancialsNewsTraderScreen

ADDEX THERAPEUTICS SA NAM.-AKTIE/  CH0029850754  /

Lang & Schwarz
2024-05-27  5:17:50 PM Chg. +0.012 Volume Bid- Ask- Market Capitalization Dividend Y. P/E Ratio
0.069EUR +21.33% -
Turnover: -		 -Bid Size: - -Ask Size: - 13.08 mill.EUR - -
GlobeNewswire 05-08 Addex to Present at Bio€quity Europe 2024
GlobeNewswire 04-29 Addex Provides Update on ADX71149 Phase 2 Epilepsy Study
GlobeNewswire 04-19 Addex to Present at the Swiss Biotech Day 2024
GlobeNewswire 04-18 Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire 04-11 Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18,...
GlobeNewswire 04-03 Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Mod...
GlobeNewswire 03-14 Addex to Present at the Bio-Europe Spring 2024 Conference
GlobeNewswire 01-31 Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.
GlobeNewswire 01-09 Addex to Present at the Swiss Equities Baader Conference
GlobeNewswire 01-05 Addex to Present at Biotech Showcase™ 2024
GlobeNewswire 2023-12-14 Addex Creates Treasury Shares
GlobeNewswire 2023-11-29 Addex Reports Q3 2023 Financial Results and Provides Corporate Update
GlobeNewswire 2023-11-28 Addex Convenes Extraordinary General Meeting
GlobeNewswire 2023-11-23 Addex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on Novem...
GlobeNewswire 2023-11-14 Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients
GlobeNewswire 2023-11-08 Addex Regains Nasdaq Listing Compliance
GlobeNewswire 2023-11-02 Addex Announces Participation in the Bio-Europe 2023 Conference
GlobeNewswire 2023-10-20 Addex Completes ADS Ratio Change
GlobeNewswire 2023-10-06 Addex Announces Plan to Implement ADS Ratio Change
GlobeNewswire 2023-09-20 Addex mGlu2 NAM Cognition Program Receives €4 Million Grant
GlobeNewswire 2023-09-06 Addex Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference
GlobeNewswire 2023-09-05 Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024
GlobeNewswire 2023-09-04 Addex’s Dipraglurant Development in Post-Stroke Recovery Supported by Data Published in Brain
GlobeNewswire 2022-03-24 Addex to Present at the Bio-Europe Spring 2022 and Maxim Group – 2022 Virtual Growth Conferences
GlobeNewswire 2022-03-10 Addex Reports Full Year 2021 Financial Results and Provides Corporate Update